Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Capital One Financial Corp. (COF) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Capital One Financial Corp.Trade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Capital One Financial Corp. vs Inovio Pharmaceuticals Inc — how do they compare? Capital One Financial Corp. trades at $222.01 (market cap $134.45B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Capital One Financial Corp. is far larger — about 1711.6× Inovio Pharmaceuticals Inc's market cap, and Capital One Financial Corp. pays a 1.46% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

COFINO
Market Cap
$134.45B$78.55M
Sector
FinancialsHealth
52-Week High
$257.94$2.87
52-Week Low
$176.10$0.66
Dividend Yield
1.46%
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Capital One Financial Corp.

Capital One Financial (COF) trades at $223.09, up 1.88% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.07 and P/B of 1.18, while Q2 2026 earnings beat expectations. Recent news highlights the Discover integration progress and a 20-year arena naming rights extension, reinforcing brand commitment.

The outlook is positive with a consensus price target of $251.60, implying 13% upside, supported by 63% analyst buy ratings. Key risks include integration execution of Discover, credit loss provisions, and macroeconomic sensitivity. Revenue growth to $62.0B in 2026 projects a net income margin rebound to 16.96%, offering a compelling value proposition if synergies materialize.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Capital One Financial Corp.

Capital One is a diversified financial services holding company headquartered in McLean, Virginia. Originally a spinoff of Signet Financial's credit card division in 1994, the company is now primarily involved in credit card lending, auto loans, and commercial lending.

Read more on COF

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO